AbbVie

Open: 149.0 Close: 147.85 Change: -1.15

Is AbbVie Company Inc Stock a good investment? This what an AI found.

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Abbvie, …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

The average analyst consensus on ABBV stock is a Moderate Buy. The company beat sales expectations with revenue of $12.23 billion, topping estimates. AbbVie avoided a sales cliff caused by the loss of Humira.

Today's News

AbbVie drops midphase psoriasis drug over toxicology data. Abbvie drops middle phase Psoriasis treatment over toxicological data. These press releases remain on AbbVies website for historical purposes only. Abbvie assumes no duty to update the information to reflect subsequent developments. The AbbVie Cystic Fibrosis (CF) Scholarship is now accepting applications for the 2023-2024 academic school year. The company will announce its first-quarter 2023 financial results on April 27. AbbVie has been a strong performer since its split from Abbott Labs, and its trying hard to keep the momentum going. The average analyst consensus on ABBV stock is a Moderate Buy. AbbVie Inc. (ABBV) stock price, quote & news - stock analysis. Abbvie is a leader in immunology and has successfully introduced autoimmune disease treatment Humira and Skyrizi. Shares of pharmaceutical giant AbbVie (NYSE: ABBV) fell by as much as 9% in early morning trading Thursday. The pharmaceutical giant reported 2023 first-quater earnings that didnt sit well. AbbVie avoided a sales cliff caused by the loss of Humira exclusivity through its 2020 acquisition of Allergan and that companies cash cow Botox. The company beat sales expectations with revenue of $12.23 billion, topping estimates. AbbVie will participate in the Bank of America Securities Healthcare Conference on Tuesday, May 9, 2023. A live audio webcast of the presentation will be accessible through Abbvies Investor Relations website at investors.abbvie.com. AbbVie jobs in may, 2023 (hiring now!). Abbvie Jobs in May, 20 23 (Hiring Now!) Jobs Sign In Careers By Job Titles By College Majors By Companies By Location. AbbVie Inc (ABBV) stock is lower by -7.15% while the S&P 500 is higher by 0.76% as of 10:15 AM on Thursday, April 27. Abbvie on track for biggest decline in about three years as newer drug sales lag estimates - marketwatch.com. AbbVie posted net income of $239 million, or 13 cents a share, for the quarter, down from $4.49 billion, or $2.51 a share in the year-ago period. The Zacks Large Cap Pharmaceuticals industry, to which Abbvie belongs, has gained five. AbbVie Inc. dropped almost 8% after its most recent earnings release, triggered by lower-than-expected guidance and a sales decline caused by the Humira patent loss. Skyrizi and Rinvoq, which treats plaque psoriasis and rheumatoid arthritis, will eventually bring in more money. AbbVie has raised 2023 EPS Guidance Range to $10.72 - $11.12. The company recently announced its 2022 ESG Action Report. AbbVie employees share photos with their families and discuss how they recognize Eid al-Fitr. Join our #investor call this Thursday, April 27 at 8am CT to share our Q1 2023 financial results.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Abbvie, company, ABBV, stock, sale, share, and the most common words in the summary are: abbvie, stock, market, news, job, abbv, new, . One of the sentences in the summary was: The average analyst consensus on ABBV stock is a Moderate Buy. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #market #news #job #abbv #new.